Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: Results of a systematic literature review and meta-analysis

Open Forum Infectious Diseases

Volumn 5, Issue 7, 2018, Pages

  Martin, Amber ^a   Fahrbach, Kyle ^a   Zhao, Qi ^b   Lodise, Thomas ^c,d  

^a EVIDERA   (United States)

^b ALLERGAN PLC   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bacterial drug resistance; Carbapenems; Klebsiella pneumoniae; Meta analysis; Mortality

Indexed keywords

CARBAPENEM; CEFTAZIDIME; COLISTIN; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIBLIOGRAPHIC DATABASE; CITROBACTER; DATA EXTRACTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; HOSPITAL MORTALITY; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; META ANALYSIS; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SERRATIA; SYSTEMATIC REVIEW; UNITED STATES; URINARY TRACT INFECTION;

EID: 85050864549     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofy150     Document Type: Review

References (28)

1. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012; 18:439-48
2. Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 2014; 46:149-64
3. Centers for Disease Control and Prevention. Healthcare-associated infections. Available at: http://www.cdc.gov/hai/organisms/cre/cre-clinicianFAQ.html. Accessed 11 July 2018
4. Moher D, Liberati A, TetzlaffJ, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097
5. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60
6. de Oliveira MS, de Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect 2015; 21:179.e1-7
7. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012; 18:54-60
8. Bleumin D, Cohen MJ, Moranne O, et al. Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients. J Infect 2012; 65:318-25
9. Brizendine KD, Richter SS, Cober ED, van Duin D. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Antimicrob Agents Chemother 2015; 59:553-7
10. Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenemnonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect 2011; 44:125-30
11. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53:1868-73
12. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-8
13. Giacobbe DR, Del Bono V, Trecarichi EM, et al.; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106.e1-8
14. Tumbarello M, Trecarichi EM, De Rosa FG, et al.; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133-43
15. Kontopidou F, Giamarellou H, Katerelos P, et al.; Group for the Study of KPCproducing Klebsiella pneumoniae infections in intensive care units. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20:O117-23
16. Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010; 31:1250-6
17. Ny P, Nieberg P, Wong-Beringer A. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections. Am J Infect Control 2015; 43:1076-80
18. Orsi GB, Bencardino A, Vena A, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study. Infection 2013; 41:61-7
19. Papadimitriou-Olivgeris M, Marangos M, Fligou F, et al. KPC-producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay: the significance of risk factors for its development and its impact on mortality. Diagn Microbiol Infect Dis 2013; 77:169-73
20. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106
21. Qureshi ZA, Paterson DL, Peleg AY, et al. Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases. Clin Microbiol Infect 2012; 18:887-93
22. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13
23. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carba-penem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028-33
24. Trecarichi EM, Pagano L, Candoni A, et al.; HeMABIS Registry-SEIFEM Group, Italy. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 2015; 21:337-43
25. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-50
26. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17:1798-803
27. Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 2013; 83:307-13
28. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36:1433-7